Munich biosensor SME offering commercial DNA/RNA interaction platforms and industry training nodes for molecular biophysics and synthetic biology consortia.
Dynamic Biosensors GmbH is a Munich-based biotech SME specializing in biosensor technology for measuring molecular interactions at the nanoscale — most likely the developer of switchSENSE, a proprietary platform that uses electrically actuated DNA nanolevers to characterize protein-nucleic acid binding kinetics. Their H2020 participation as an industry partner in Marie Skłodowska-Curie training networks (MSCA-ITN) indicates they host and co-supervise doctoral researchers, embedding their commercial instrumentation into academic research workflows. Their project portfolio spans from fundamental photodynamics of DNA and RNA structures to applied synthetic biology and protein engineering, placing them at the intersection of molecular biophysics and analytical instrumentation. As an SME they bring both scientific depth and a commercially deployable technology platform to collaborative research.
Both projects (LightDyNAmics, RNAct) were hosted in part by Dynamic Biosensors as an industry MSCA partner, integrating their biosensor platform into nucleic acid and protein interaction studies.
LightDyNAmics focused on DNA photophysics and excited-state dynamics, while RNAct targeted RNA recognition motifs and protein-RNA binding — both directly relevant to biosensor readout mechanisms.
LightDyNAmics (2018) covered pump-probe and 2D spectroscopy, charge transfer, and guanine quadruplex photophysics — foundational for understanding DNA-based biosensor signal transduction.
RNAct (2019) introduced synthetic biology and engineered proteins with RNA recognition motifs, marking a shift toward functional biomolecular design rather than pure characterization.
In their first H2020 project (2018), Dynamic Biosensors contributed to fundamental research on the photophysics and excited-state dynamics of DNA — nucleobases, guanine quadruplexes, charge transfer, and computational spectroscopy. This reflects their grounding in the physical behaviour of nucleic acid structures, which underpins the signal physics of their biosensor platform. By 2019, the keyword profile shifted decisively toward synthetic biology, protein design, and bio-analytics, suggesting the company moved from characterizing natural DNA behaviour to enabling engineered biomolecular systems with designed function. The trajectory points toward expanding from measurement instrument supplier into a technology enabler for designed protein-nucleic acid assemblies.
Dynamic Biosensors appears to be broadening from pure biophysical characterisation toward synthetic biology applications, positioning their platform as a tool for validating engineered proteins and RNA-binding molecules — a market with growing demand in drug discovery and diagnostics.
Dynamic Biosensors has participated exclusively as a consortium partner and has never coordinated an H2020 project, which is typical for SMEs joining MSCA-ITN networks as industry training hosts rather than scientific leaders. Both projects were large multi-partner training consortia (an MSCA-ITN typically involves 8-15 nodes), meaning the company operates within structured academic-industry networks rather than leading bilateral research partnerships. This profile suggests they are pragmatic, service-oriented collaborators who contribute instrumentation access, industrial training capacity, and applied context rather than driving project strategy.
Despite only two projects, Dynamic Biosensors has built connections with 28 unique consortium partners across 13 countries, reflecting the broad multi-node structure of MSCA-ITN consortia. Their network is pan-European in character, with no visible geographic concentration beyond Germany as their home base.
Dynamic Biosensors occupies a rare niche as a German deep-tech SME that bridges commercial biosensor instrumentation with frontier academic research in molecular biophysics and synthetic biology — most companies in this space are either pure instrument vendors or pure research labs, not both. Their MSCA-ITN participation means they have a proven track record of hosting and co-supervising doctoral researchers, making them an attractive industry node for future training networks that need credible SME partners with real technology. For a consortium builder, they offer not just scientific expertise but a deployable commercial platform that can turn research results into validated, instrument-ready assays.
